A five-year clinical study of the Essilor Stellest lenses has demonstrated continued long-term efficacy in controlling myopia progression and axial elongation.
The controlled, prospective, randomised clinical trial which began in 2018 was conducted at the Eye Hospital of Wenzhou Medical University in Wenzhou, China.
The age of the children at enrolment in 2018 was eight to 13 years old. To assess the long-term efficacy, the study was extended from the original two-year clinical trial to five years.
The data showed that Essilor Stellest lenses slowed myopia progression by 1.75D*1 and axial elongation by 0.72mm**1 on average over five years for all subjects, compared to the extrapolated control group, showing conclusive evidence of their efficacy in slowing down myopia progression in children in the fifth year.
The data also showed that the efficacy in slowing myopia progression and axial elongation was sustained in older children (up to 18 years old), as the children who completed the fifth-year study were aged between 13-18 years.
It is planned to continue the study for two more years, to gauge the seven-year myopia control efficacy of the lens.
Mr Norbert Gorny, chief scientific officer at EssilorLuxottica, said: “We are excited to be able to share the latest five-year findings of Essilor Stellest lenses as long-term clinical data is essential to showcase the continued efficacy and performance of the lens in children.
“As we already know that every dioptre matters, we look forward to sharing scientific data and insights on interventions to address myopia, to bring us all one step closer to protecting the vision of young patients.”
He added: “We will also continue to integrate scientific knowledge with innovative technologies to create the future of myopia control spectacle lenses so that the next generation can see more and be more.”
More reading
New four-year data for Essilor Stellest lens
Essilor Stellest myopia control lens launches in Australia and New Zealand
Managing myopia with spectacle lenses
References
*Compared to the 60-month progression of the extrapolated control group (predicted average annual decrease in SER by 9.7% based on the initial 2-year control group, Smotherman C, et al. IOVS 2023;64:ARVO E-Abstract 811).
**Compared to the 60-month progression of the extrapolated control group (predicted average annual decrease in AL by 15% based on the initial 2-year control group, Shamp W, et al. IOVS 2022;63:ARVO E-Abstract A0111)
1. Li X, Huang Y, Liu C, Yin Z, Cui Z, Lim EW, Drobe B, Chen H, Bao J. Myopia control efficacy of Spectacle Lenses with Highly Aspherical Lenslets: results of a 5-year follow-up study. ARVO Annual Meeting, Seattle. 2024. Available at: https://eppro02.ativ.me/web/page.php?nav=false&page=IntHtml&project=ARVO24&id=4045389&external=true
